I would guess that companies with similar products have already taken notice
We have also seemed to have a few new posters on the forum that seem to see all bad?
Overall it looks like the product is working
In the BTX 1503 QD group, efficacy outcomes in both Australia and the USA were in line with
inflammatory lesion reduction (40.4% reduction in the USA versus a 40.8% reduction in Australia) and
non-inflammatory lesion reduction (33.3% in the USA versus 38.1% in Australia).
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-149
-
- There are more pages in this discussion • 254 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |